In the News
Grants from the Bill & Melinda Gates Foundation support the optimization of the Dahlia™ small-footprint protein manufacturing system and the de-risking of several protein candidates using Sunflower’s proprietary manufacturing approach.
Sunflower Therapeutics, a public benefit corporation focused on transforming access to biologics medicines for patients worldwide, has delivered its first system for biomanufacturing, the Daisy Petal™ fermentation system.
Roivant Social Ventures (RSV), a not-for-profit social impact organization launched out of Roivant Sciences, today unveiled its executive team and announced its inaugural partnership with Sunflower Therapeutics, a biopharmaceutical company developing simplified manufacturing methods for therapeutic proteins.
Sunflower Therapeutics, a public benefit corporation focused on improving access to biologic medicines for patients worldwide, announced that it was granted a second phase of funding to support an existing award made by the Bill & Melinda Gates Foundation to further the foundation’s charitable purpose of improving global health. This award will support the development of a laboratory-scale, deployable manufacturing system and will culminate in the demonstrated production of a protein subunit for a COVID-19 vaccine candidate later this year.
Sunflower Therapeutics, a public benefit corporation focused on efficient manufacturing for proteins, announced that it has donated $25,000 of its profits earned in 2020 to four non-profit organizations focused on serving the global poor.
Sunflower Therapeutics, a public benefit corporation focused on efficient manufacturing for proteins, announced that it has been awarded a $5.7 million extension of an existing contract with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) for the purpose of developing a Biologics on Demand (BOD) manufacturing prototype for recombinant protein-based medical countermeasures (MCMs).
Today, vaccines and other protein-based biologic drugs are typically made in large, dedicated manufacturing facilities. But that doesn’t always fit the need, and it could one day change. A team of researchers has engineered a miniaturized biopharmaceutical “factory” that could fit on a dining room table and produce hundreds to thousands of doses of a needed treatment in about three days.
Today there’s essentially one model for drug production: make as much as possible. But J. Christopher Love, a professor of chemical engineering at the Massachusetts Institute of Technology, has spent the last five years pursuing a different vision: a desktop drug manufacturing process that would be fast and nimble enough to help combat a small disease outbreak, treat an unusual cancer, or replace a rare enzyme.
An all-in-one bench-top system can churn out hundreds or thousands of doses of a medically useful protein in a few days — and can easily switch to manufacturing other proteins.